Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
NCT06226662 is registered in ClinicalTrials.gov with NovelMed Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
- Lead sponsor
- NovelMed Therapeutics
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- September 30, 2028
- Enrollment
- 12 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.